Pharmaceutical formulations for subcutaneous administration of furosemide
US12370168B2 · kind B2 · utility
0Cited by
11References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 2022 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Aug 5, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.